Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Brazil / NCT06807762
Recruiting Phase 1

Safety and Pharmacokinetics of Extrato de Cannabis Sativa GreenCare

NCT06807762 · tracked via the Priya Life Science Brazil tracker
Sponsor
GreenCare Pharma
Phase
Phase 1
Started
2025-03-18
Last updated
2025-03-21

Condition(s) studied

Healthy

Investigational drug(s) / intervention(s)

Cannabis oil →

Cannabis oil: Healthy subjects will be treated with a solution of Cannabis sativa extract diluted in MCT oil, at doses ranging from 39.62 mg to 791.4 mg. This protocol will be divided into two stages: Stage 1 - Determination of the Maximum Tolerated Dose (MTD): Participants (n=60) will be dynamically randomized and will receive Cannabis sativa extract (GreenCare, 79.14 mg/mL) as a single dose after breakfast, with doses ranging from 39.62 mg to 791.4 mg. Stage 2 - Assessment of the MTD: All participants (n=12) will receive the MTD determined in Stage 1, administered in two daily doses for 14 consecutive days.

Study summary

The goal of this Phase I clinical trial is to assess the pharmacokinetic availability and safety and tolerability profile of Extrato de Cannabis sativa GreenCare 79.14 mg/mL. The main question it aims to answer is:

• Is the Extrato de Cannabis sativa GreenCare 79,14 mg/mL safe?

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Men and women from 18 to 65 years, inclusive; * Body weight ≥ 50 kg and BMI between 18.5 and 30 kg/m2, inclusive; * Be healthy according to medical history, i.e., have laboratory test results within normal ranges and/or any deviations from normal classified as clinically insignificant; * Be exclusively participating in this clinical study during the research period; * Understand and comply with the protocol requirements and consent to participate in the study by signing the Informed Consent Form (ICF) approved by an Ethics Committee (EC). Exclusion Criteria: Having participated in any experimental study or ingested any experimental drug within 1 (one) year prior to the start of this study; * Inability to use oral medication and/or cooperate with investigators due to cognitive impairment or mental state; * Reported allergy to any component of Cannabis sativa extract 79.14 mg/mL; * Personal or first-degree family history of schizophrenia, bipolar affective disorder, psychotic symptoms, suicidal ideation, planning and/or attempt, and/or severe uncontrolled psychiatric comorbidities, at the discretion of the principal investigator; * Donated blood within four (4) months prior to signing the Informed Consent Form (ICF); * Being pregnant, breastfeeding, intending to become pregnant during the study period, or having a positive result for urinary β-HCG testing; * Reported use of Cannabis and/or its derivatives for any purpose in the past 6 months; * Personal history of Cannabis use disorder and/or other illicit drug use disorder; * Personal history of alcohol, tobacco, opioid, benzodiazepine, barbiturate, and/or other substance use disorders, such as St. John's Wort; * Smokers or ex-smokers who quit less than 6 months ago; * Consumed alcoholic beverages within 24 hours before the study confinement period; * Any condition that prevents participation at the discretion of the investigator; * Dietary habits that prevent ingestion of the diet provided during the study; * Any clinical or laboratory finding or therapy that, at the investigator's discretion, may place the participant at risk or interfere with study objectives or outcomes; * Non-compliance with the complete ingestion of the diet provided - determination at the discretion of the responsible physician.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
GreenCare Pharma Vinhedo São Paulo Recruiting

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06807762 on ClinicalTrials.gov ↗ ← All trials in Brazil